Haemolytic anaemia triggered by antitumoural “biological agents” and immunotherapies with monoclonal antibodies: short review of the literature
First Online: 14 April 2010 DOI:
Cite this article as: Sun, W.L., Walder, A. & Fiegl, M. memo (2010) 3: 19. doi:10.1007/s12254-010-0174-y
In the last decade, many novel immunomodulating therapies and “biologicals”, usually acting as signal transduction inhibitors, came into routine therapy in cancer. Mostly, these substances are well tolerated, and there is a typical spectrum of common side effects to be considered with these therapies. A rather rarely seen toxic effect associated with the administration of these agents is haemolytic anaemia (HA). Here, we shortly summarize current knowledge on HA potentially triggered by these substances. Furthermore, an impressive case of myelodysplastic syndrome with 5q deletion which received lenalidomide and developed autoimmune haemolytic anaemia (AIHA) is presented.
Keywords Haemolytic anaemia biologicals therapeutic antibodies lenalidomide
Received 12 January 2010; accepted 19 January 2010
List A, Kurtin S and Roe DJ et al. (2005). Efficacy of lenalidomide in myelodysplastic syndromes.
N Engl J Med
Darabi K, Kantamnei S, Wiernik PH. Lenalidomide-induced warm autoimmune hemolytic anemia. J Clin Oncol, 24: e59, 2006.
Sun WL, Koeck L, Walder A, et al. Successful treatment of MDS with lenalidomide, complicated by transient autoimmune hemolysis. Anna Hematol, Epub ahead of print
Faderl S, Rai K and Gribben J et al. (2006). Phase II study of single-agent Bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Novaretti MCZ, Fonseca GHH and Conchon M et al. (2003). First case of immune- mediated haemolytic anaemia associated to imatinib mesylate.
Eur J Haematol
De Arriba JJ, Nerin C and Garcia E et al. (2003). Severe hemolytic anemia and skin reaction in a patient treated with imatinib.
Jain R, Mathew P and Wood CG et al. (2008). Sunitinib-induced acute hemolysis without hypertension: a case report.
Clin Genitourin Cancer
Berchem G, Dewilde S and Mahassen P (2009). A case of acute haemolysis with 2 diff erent multi target thyrosine kinase inhibitors in a patient with renal cancer.
Bull Soc Sci Med Grand Duche Luxemb
Ruch J, McMahon B and Ramsey G et al. (2009). Catastrophic multiple organ ischemia due to an anti-Pr cold agglutinin developing in a patient with mixed cryoglobulinemia after treatment with rituximab.
Am J Hematol
Ramamoorthy SK, Marangolo M and Durrant E et al. (2006). Unusual reaction to Rituximab with intra-vascular hemolysis, rhabdomyolysis, renal failure and bone marrow necrosis.
Jourdan E, Topart D and Richard B et al. (2003). Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder.
Elimelakh M, Dayton V and Park KS et al. (2007). Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients.
Kako S, Kanda Y and Oshima K et al. (2008). Late onset of autoimmune hemolytic anemia and pure red cell aplasia after allogeneic hematopoietic stem cell transplantation using in vivo alemtuzumab.
Am J Hematol
Fiegl M, Falkner A and Hopfinger G et al. (2006). Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia.
Wierda WG, Kipps TJ, Keating MJ, et al. Self-administered, subcutaneous alemtuzumab to eliminate residual disease in patients with CLL. Blood, 108(abstract 2839), 2006.
Frangie C, Lefaucheur C and Medioni J et al. (2007). Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.
Eremina V, Jefferson JA and Kowalewska J et al. (2008). VEGF inhibition and renal thrombotic microangiopathy.
N Engl J Med
Galesic K, Bozic B and Racic I et al. (2006). Thrombotic microangiopathy associated with σ-interferon therapy for chronic myeloid leukemia.
Sacchi S, Kantarjian H, O’Brien S, Cohen PR, Pierce S and Talpaz M (1995). Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia.
J Clin Oncol
Takase K, Nakano T, Hamada M, Shiraki K, Oohashi Y, Kihira T and Tameda Y (1995). Hemolytic anemia provoked by recombinant alpha-interferon.
Cauli C, Serra G and Chessa L et al. (2006). Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin.
Haematologica 91: e76–e77
Lambotte O, Gelu-Simeon M and Maigne G et al. (2005). Pegylated interferon alpha-2a-associated life-threatening Evens’ syndrome in a patient with chronic hepatitis C.
Weiss RB, Freiman J and Kweder SL et al. (1998). Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.
J Clin Oncol
Borthakur G, O’Brien S and Wierda WG et al. (2007). Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab – incidence and predictors.
Br J Haematol
Robak T (2004). Monoclonal antibodies in the treatment of autoimmune cytopenias.
Eur J Haematol
Giagounidis AA, Haase S and Germing U et al. (2005). Autoimmune disorders in two patients with myelodysplastic syndrome and 5q deletion.
Novaretti MC, Sopelete CR and Velloso ER et al. (2001). Immunohematological findings in myelodysplastic syndrome.
Wolf D. (2009). IMiDs induce pleiotropic anti-cancer effects..
Suppl 1: 10–12